Table 1 Distribution of the breast cancer patient based on clinicopathological Features and hormonal receptors
Clinicopathological Features | No | % |
|---|---|---|
Tumor side | ||
Right | 33 | 44.0 |
Left | 42 | 56.0 |
Pathological subtype | ||
IDC | 65 | 86.7 |
ILC | 6 | 8.0 |
Mixed IDC and ILC | 2 | 2.7 |
Other | 2 | 2.7 |
Pathological stage | ||
Stage 1 | 6 | 8.0 |
Stage 2 | 25 | 33.3 |
Stage 3 | 30 | 40.0 |
Stage 4 | 14 | 18.7 |
Metastasis Status | ||
No | 54 | 72.0 |
Yes | 21 | 28.0 |
Grade | ||
Grade I | 1 | 1.3 |
Grade II | 68 | 90.7 |
Grade III | 6 | 8.0 |
PT status | ||
T1 | 9 | 12.0 |
T2 | 36 | 48.0 |
T3 | 23 | 30.7 |
T4 | 7 | 9.3 |
PN status | ||
N0 | 15 | 20.0 |
N1 | 29 | 38.7 |
N2 | 17 | 22.7 |
N3 | 14 | 18.7 |
Toxicity grade | ||
No Toxicity | 56 | 74.7 |
Grade 1 | 7 | 9.3 |
Grade 2 | 4 | 5.3 |
Grade 3 | 8 | 10.7 |
Hormonal receptors | ||
ER | 44 | 58.7 |
PR | 42 | 56.0 |
HER2/neu | 16 | 21.3 |
Ki 67 | ||
Not done | 14 | 18.7 |
Low (< 14) | 16 | 21.3 |
High (equal or > 14) | 45 | 60.0 |
Molecular subtype | ||
Basal (Triple negative) | 25 | 33.3 |
HER2/neu overexpressed | 6 | 8.0 |
Luminal A | 13 | 17.3 |
Luminal B | 31 | 41.3 |